Chicago, Illinois

Chicago, Illinois 60641-4023

0 studies enrolling now · 5 studies all time

What they study most

Parkinson Disease, Schizophrenia

Studies at this site

• Open-label Trial in Parkinson's Disease (PD) — Completed
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia — Completed
• Fixed-Dose Trial in Early Parkinson's Disease (PD) — Completed
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia — Completed
• Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) — Completed